A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy J. Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédéric Selle, Mansoor R. Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh K.B. Parmar, Amit M. Oza

Open source

DOI: 10.1056/nejmoa1103799
Published: 2011-12-29
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1103799,
  title = {A Phase 3 Trial of Bevacizumab in Ovarian Cancer},
  author = {Timothy J. Perren and Ann Marie Swart and Jacobus Pfisterer and Jonathan A. Ledermann and Eric Pujade-Lauraine and Gunnar Kristensen and Mark S. Carey and Philip Beale and Andrés Cervantes and Christian Kurzeder and Andreas du Bois and Jalid Sehouli and Rainer Kimmig and Anne Stähle and Fiona Collinson and Sharadah Essapen and Charlie Gourley and Alain Lortholary and Frédéric Selle and Mansoor R. Mirza and Arto Leminen and Marie Plante and Dan Stark and Wendi Qian and Mahesh K.B. Parmar and Amit M. Oza},
  year = {2011},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa1103799},
  url = {https://doi.org/10.1056/nejmoa1103799}
}

RIS

TY  - JOUR
TI  - A Phase 3 Trial of Bevacizumab in Ovarian Cancer
AU  - Timothy J. Perren
AU  - Ann Marie Swart
AU  - Jacobus Pfisterer
AU  - Jonathan A. Ledermann
AU  - Eric Pujade-Lauraine
AU  - Gunnar Kristensen
AU  - Mark S. Carey
AU  - Philip Beale
AU  - Andrés Cervantes
AU  - Christian Kurzeder
AU  - Andreas du Bois
AU  - Jalid Sehouli
AU  - Rainer Kimmig
AU  - Anne Stähle
AU  - Fiona Collinson
AU  - Sharadah Essapen
AU  - Charlie Gourley
AU  - Alain Lortholary
AU  - Frédéric Selle
AU  - Mansoor R. Mirza
AU  - Arto Leminen
AU  - Marie Plante
AU  - Dan Stark
AU  - Wendi Qian
AU  - Mahesh K.B. Parmar
AU  - Amit M. Oza
PY  - 2011
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa1103799
UR  - https://doi.org/10.1056/nejmoa1103799
ER  -

APA

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., Bois, A. D., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K., & Oza, A. M. (2011). A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1103799

Source records

crossref · retrieved 2026-09-25T01:45:51.429Z